Literature DB >> 1761807

In vivo insulin action in hepatocellular and cholestatic liver cirrhosis.

N Barzilai1, P Cohen, E Karnieli, R Enat, O Epstein, J Owen, N McIntyre.   

Abstract

The in vivo dose response curve to insulin were studied, using an euglycemic insulin clamp technique, in 13 cirrhotic patients [8 with "hepatocellular" (HC) (nonalcoholics) and 5 with "cholestatic" (CHOL) cirrhosis] and 12 healthy controls (N). Subjects were studied in the basal state and during infusion of insulin at 3 different rates - 1, 3, 10 mU kg-1 min-1. Insulin responsiveness was similar in N and in HC, but it was 23% greater in CHOL (p less than 0.001). Insulin sensitivity was decreased in cirrhotics as compared with N but this difference was only significant (p less than 0.001) in HC. (ED50:62 + 5, 88 + 13 and 136 + 16 muu ml-1 in N, CHOL and HC respectively). Insulin clearance rate (ICR) was significantly (p less than 0.005) decreased in HC (1060 +/- 80, 996 +/- 95 and 776 +/- 128 ml sq m-1 ml-1 in N, CHOL and HC respectively. Basal hepatic glucose production (BHGP) was 39% lower in HC (p less than 0.005) and 24% lower in CHOL (p less than 0.05) than in N. Erythrocyte cholesterol phospholipid ratio was significantly elevated (p less than 0.001) in both groups of cirrhotic patients but was not correlated to specific metabolic changes described. In summary: i) intervariations in insulin dependent glucose metabolism were described in different cirrhotic groups; ii) basal hepatic glucose production and insulin clearance rate impaired in the different groups of cirrhotics; iii) the role of decreased cholesterol/phospholipid ratio on tissues glucose metabolism in cirrhotic patients should be further studied.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1761807     DOI: 10.1007/BF03347904

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  41 in total

1.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

2.  Effect of bilayer cholesterol content on reconstituted human erythrocyte sugar transporter activity.

Authors:  T J Connolly; A Carruthers; D L Melchior
Journal:  J Biol Chem       Date:  1985-03-10       Impact factor: 5.157

3.  C-peptide in non-alcoholic cirrhosis and hepatocellular carcinoma.

Authors:  K K Pun; P W Ho; R T Yeung
Journal:  J Endocrinol Invest       Date:  1988-05       Impact factor: 4.256

4.  Feedback inhibition of insulin secretion is altered in cirrhosis.

Authors:  P Cavallo-Perin; A Bruno; P Nuccio; M Goria; G Pagano; G Lenti
Journal:  J Clin Endocrinol Metab       Date:  1986-10       Impact factor: 5.958

Review 5.  Membrane lipid composition and cellular function.

Authors:  A A Spector; M A Yorek
Journal:  J Lipid Res       Date:  1985-09       Impact factor: 5.922

6.  Decreased erythrocyte membrane fluidity and altered lipid composition in human liver disease.

Authors:  J S Owen; K R Bruckdorfer; R C Day; N McIntyre
Journal:  J Lipid Res       Date:  1982-01       Impact factor: 5.922

7.  Glucose turnover in compensated hepatic cirrhosis.

Authors:  D M Piniewska; A J McCulloch; M G Bramble; R Taylor; C O Record; K G Alberti
Journal:  Horm Metab Res       Date:  1986-12       Impact factor: 2.936

8.  Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes.

Authors:  A V Greco; A Bertoli; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi
Journal:  Horm Metab Res       Date:  1980-11       Impact factor: 2.936

9.  Reconstituted human erythrocyte sugar transporter activity is determined by bilayer lipid head groups.

Authors:  R E Tefft; A Carruthers; D L Melchior
Journal:  Biochemistry       Date:  1986-06-17       Impact factor: 3.162

10.  Hyperinsulinaemia and insulin resistance of cirrhosis: the importance of insulin hypersecretion.

Authors:  J Proietto; F J Dudley; P Aitken; F P Alford
Journal:  Clin Endocrinol (Oxf)       Date:  1984-12       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.